Orchard Rx Ltd. ORTX 深 沪
等待开盘 07-10 09:30:00 美东时间
16.70
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 16.70
- 总市值 37.95万
- 52周最高 16.72
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.24
- 委 比 0.00%
- 总股本 2.27万
- 历史最高 216.40
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.601
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AI startup CEO pleaded guilty in US to trading on insider tips from lawyers
AI startup CEO pleaded guilty in US to trading on insider tips from lawyers Prosecutors recommend two years in prison for AppliedAI's founder Nine other defendants have also pleaded guilty in proceedings before indictments announced Authorities say Arya Bolurfrushan's trades generated about $954,000
07-07 22:33
Kyowa Kirin’s rare disease therapy becomes world’s most expensive drug
Orchard Therapeutics (ORTX), recently acquired by Kyowa Kirin (OTCPK:KYKOY), has set its newly FDA-approved rare disease therapy Lenmeldy at a wholesale price of $4.25M on Wednesday, making one-time g...
2024-03-21 00:11
XORTX Reprices Warrants Issued in Connection With Previous Private Placements
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION I...
2024-03-11 19:00
Kyowa Kirin Completes Acquisition Of Orchard Therapeutics
The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024, and Orchard Therapeutics has become a
2024-01-24 18:34
XORTX Announces $2 Million Public Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN...
2024-01-15 08:00
Orchard Therapeutics Wins Swissmedic Approval for Libmeldy in Early-Onset Metachromatic Leukodystrophy (MLD)
Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy® (atidarsagene autotemcel), a hematopoietic stem
2023-12-11 20:02
Orchard Therapeutics 凭借 MPS-IH 中的 OTL-203 获得美国食品药品管理局快速通道称号
Previously reported results from ongoing proof-of-concept study showed extensiv...
2023-11-30 08:00
Orchard Therapeutics: Q3 Earnings Insights
Orchard Therapeutics (NASDAQ:ORTX) reported its Q3 earnings results on Monday, ...
2023-11-13 20:15
ALERT: The M&A Class Action Firm Continues Investigating the Merger - ORTX, SRT, CHS, ICPT
NEW YORK, Oct. 23, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities...
2023-10-24 08:55
